Sarcoma's Many Subtypes Complicate Treatment Progress: Alexander Spira, MD, PhD

Alexander Spira, MD, PhD, medical oncologist at Virginia Cancer Specialists and chief scientific officer of NEXT Oncology, discusses why treatment advances in sarcoma have lagged behind other solid tumors, pointing to disease heterogeneity and inconsistent responses to newer therapies as key barriers.

Spira explains that chemotherapy remains the backbone of treatment for most patients with sarcoma, despite offering only modest benefit. For soft tissue sarcomas specifically, doxorubicin-based regimens are still the standard approach, sometimes paired with other agents such as dacarbazine or trabectedin. Beyond this first-line setting, Spira notes, options thin out quickly, with few novel therapies available and outcomes that amount to "rearranging the deck chairs" rather than meaningful progress.

A central reason for this stagnation, Spira explains, is that sarcoma is not a single disease but a basket of many distinct subtypes, making it difficult to study and to develop therapies that work broadly across the category. While targeted therapies exist for some sarcomas, Spira notes that they often underperform, with occasional exceptions where outcomes are unexpectedly favorable. Immunotherapy follows a similar pattern where it can be highly effective in select subtypes but fails to deliver meaningful benefit in most cases.

Spira's comments underscore a persistent unmet need in sarcoma care, where the rarity and molecular diversity of the disease have slowed the kind of drug development progress seen in more common cancers. The throughline across his commentary is the importance of recognizing tumor heterogeneity as a driver of both treatment selection and the pace of innovation.

For managed care stakeholders, Spira's remarks highlight why sarcoma continues to rely on decades-old chemotherapy regimens and why payers and health systems should anticipate a slower, more fragmented pipeline of novel therapies, as new drugs are likely to be developed for narrower, subtype-specific populations rather than across sarcoma as a whole.